Zimbabwe's govt pledges to back local medicine production

5 January 2010

The government of Zimbabwe is set to support the production of medical drugs locally in the next three years with a view to improving availability and affordability instead of relying on imports, the Short Term Emergency Recovery Pro-gramme two (STERP II) has indicated, reported the local newspaper The Herald.

According to the 2010-12 STERP II, this support would go a long way toward reducing costs of health care and its services. In order to make health care affordable, the government says it will support low-cost local production of drugs and other competitive supply arrangements which reduce the costs of medical care services."

Reliance on medical aid societies would also be of paramount significance as the government addresses challenges of emergency and unexpected financial burdens on patients. Although STERP 1 emphasizes improving drug supply and affordability, challenges still remain as Government failed to meet its target of drugs supply.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical